Brain tumours

Stem cells from bone marrow are being investigated as possible ways to assist recovery for patients with brain tumours. Click on the link provided to find out more about each trial. It remains too early to know which approach will be most suitable. We need evidence collected in clinical trials to determine if a proposed stem cell treatment is both safe and effective.

tagged as Brain tumours

  • High Dose Chemotherapy and Autologous Transplant for Neuroblastoma Location: US
    Overview: This trial is seeking to determine if blood stem cells can assist children with a very aggressive brain tumour known as neuroblastoma. In the study, blood stem cells will be collected from the patients (following G-SCF administration) and then transplanted after the patient has received high-dose chemotherapy. The patients will also receive radiotherapy and additional chemotherapy as required. The patient will be monitored to see if the transplant was successful. This trial is being conducted by the Masonic Cancer Centre in Minneapolis in the US and is expected to enrol 20 patients by February 2018.
    Link to Clinical Registry
    Trial Design: Therapeutic intervention
    Status: Open - Recruiting
    Stem Cell: Adult Bone Marrow Stem Cells
  • Gene Therapy and Chemotherapy for the Treatment of Childhood Brain Tumours Location: Australia
    Overview: This trial aims to assess the safety and effectiveness of using blood stem cells that have been genetically modified to treat children with brain tumours. The clinical trial is being conducted by the Kids Cancer Project in Alexandria New South Wales in conjunction with the Australian Department of Innovation, Industry Science and Research. The trial hopes to recruit 15 children with either high grade primary Glioma or lower grade recurrent brain tumours such as Glioma, Ependymoma, Medulloblastoma or teratogenic tumours among others. Stem cells will be harvested from the participant's blood after they have received an injection of granulocyte colony stimulating factor (G-CSF) to release the stem cells from their bone marrow. The stem cells will be genetically modified in the laboratory to make them more resistant to chemotherapy drugs. The trial participants will receive an intravenous (IV) infusion of these expanded, modified stem cells, and then 21 days later be treated with standard chemotherapy for such tumours. Participants will be monitored for complications and the effectiveness will be assessed by conducting MRI scans of the brain. The trial commenced in July 2012.
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Open - Recruiting
    Stem Cell: Adult Bone Marrow Stem Cells
  • Proteome-based Personalized Immunotherapy of Glioblastoma Location: Russia
    Overview: This trial is investigating the safety and effectiveness of a personalised immunotherapy for patients with recurrent or untreatable malignant brain tumours. The trial is being conducted by the NeuroVita Clinic of Interventional and Restorative Neurology and Therapy in conjunction with Blokhin's Russian Cancer Research Center and proposes to enrol 60 patients by invitation only between December 2012 & and December 2017. The trial is comparing the use of a combination either of cytotoxic lymphocytes harvested from the patient's blood after administration of the dendritic vaccine with either donated blood stem cells (first experimental group), or the patient's own blood stem cells (second experimental group). Participants will be monitored for complications and assessed for changes in their clinical condition, including disappearance of tumour and greater than 50% reduction in tumour size.
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Not yet started
    Stem Cell: Adult Blood Stem Cells